{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:36:21Z","timestamp":1760132181363},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.ygyno.2011.08.015","type":"journal-article","created":{"date-parts":[[2011,9,26]],"date-time":"2011-09-26T13:11:00Z","timestamp":1317042660000},"page":"505-510","source":"Crossref","is-referenced-by-count":7,"title":["Health-related quality of life outcomes of docetaxel\/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: Results from a randomized clinical trial"],"prefix":"10.1016","volume":"123","clinical-trial-number":[{"clinical-trial-number":"nct00090610","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Robin","family":"Pokrzywinski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry E.","family":"Puls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George S.","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert V.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence R.","family":"Nycum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew F.","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis A.","family":"Revicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.08.015_bb0005","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0010","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0015","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2165\/00003495-200868060-00004","article-title":"Pharmaceutical management of ovarian cancer: current status","volume":"68","author":"Markman","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0020","series-title":"Outcomes assessment in cancer: measures, methods, and applications","author":"Lipscomb","year":"2005"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0025","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1200\/JCO.2007.12.4644","article-title":"Patient-reported outcomes assessment in cancer trials: taking stock, moving forward","volume":"25","author":"Lipscomb","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0030","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1023\/A:1008996223999","article-title":"Recommendations on health-related quality of life research to support labeling and promotional claims in the United States","volume":"9","author":"Revicki","year":"2000","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0035","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/annonc\/mdi147","article-title":"Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study","volume":"16","author":"Gonzalez-Martin","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0040","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2011.08.015_bb0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1525-1438.2005.15355.x","article-title":"Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer","volume":"15","author":"Pfisterer","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","article-title":"Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy","volume":"4","author":"Bookman","year":"1999","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ygyno.2011.08.015_bb0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ygyno.2004.03.047","article-title":"The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in-vitro study","volume":"94","author":"Horowitz","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","article-title":"Second-line treatment of ovarian cancer","volume":"5","author":"Markman","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0065","article-title":"A multicenter randomized, phase II study to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer","author":"Alvarez Secord","year":"2010"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0070","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2001.19.6.1809","article-title":"Reliability and validity of the functional assessment of cancer therapy-ovarian","volume":"19","author":"Basen-Engquist","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0075","series-title":"Nutritional oncology","author":"Heber","year":"2006"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0080","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/(SICI)1097-0258(19980315\/15)17:5\/7<781::AID-SIM821>3.0.CO;2-O","article-title":"Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials","volume":"17","author":"Fairclough","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0085","series-title":"Quality of life: assessments, analysis and interpretation","author":"Fayers","year":"2000"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0090","series-title":"Linear mixed models in practice: a SAS-oriented approach","author":"Verbeke","year":"1997"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0095","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0959-8049(00)00369-5","article-title":"Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report","volume":"37","author":"Cull","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0110","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2011.08.015_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.26199","article-title":"Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer","author":"Havrilesky","year":"2011","journal-title":"Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811007001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811007001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T01:26:16Z","timestamp":1593048376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811007001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0090825811007001"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.08.015","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}